BRISTOL-MYERS SQUIBB COMPANY Proceeds from Long-Term Debt Issued
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Proceeds from Long-Term Debt Issued of $5.74 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2026-02-11
- BRISTOL-MYERS SQUIBB COMPANY proceeds from issuance of long-term debt for the quarter ending 2025-12-31 was $5.74B.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from issuance of long-term debt for the quarter ending 2025-09-30 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from issuance of long-term debt for the quarter ending 2025-06-30 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from issuance of long-term debt for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from issuance of long-term debt for fiscal 2025 was $5.74B, a 55.45% decline from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from issuance of long-term debt for fiscal 2024 was $12.88B, a 189.18% increase from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from issuance of long-term debt for fiscal 2023 was $4.46B, a 24.82% decline from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from issuance of long-term debt for fiscal 2022 was $5.93B.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $5.74B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $5.74B derived: sum of 2 quarters · filed 2026-02-11 | $5.74B derived: sum of 3 quarters · filed 2026-02-11 | $5.74B 10-K · filed 2026-02-11 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $0.00 derived: sum of 2 quarters · filed 2025-10-30 | $0.00 10-Q · filed 2025-10-30 | $0.00 derived: sum of 4 quarters · filed 2026-02-11 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $0.00 10-Q · filed 2025-07-31 | $0.00 derived: sum of 3 quarters · filed 2026-02-11 | $0.00 derived: sum of 4 quarters · filed 2026-02-11 |
| 2025-03-31 | $0.00 10-Q · filed 2025-04-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $0.00 derived: sum of 3 quarters · filed 2026-02-11 | $0.00 derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $0.00 derived: sum of 3 quarters · filed 2026-02-11 | $12.88B 10-K · filed 2026-02-11 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $0.00 derived: sum of 2 quarters · filed 2025-10-30 | $12.88B 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $12.88B 10-Q · filed 2025-07-31 | ||
| 2024-03-31 | $12.88B 10-Q · filed 2025-04-24 | |||
| 2023-12-31 | $4.46B 10-K · filed 2026-02-11 | |||
| 2022-12-31 | $26.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $26.00M derived: sum of 2 quarters · filed 2025-02-12 | $26.00M derived: sum of 3 quarters · filed 2025-02-12 | $5.93B 10-K · filed 2025-02-12 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $0.00 derived: sum of 2 quarters · filed 2023-10-26 | $5.90B 10-Q · filed 2023-10-26 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-27 | $5.90B 10-Q · filed 2023-07-27 | ||
| 2022-03-31 | $5.90B 10-Q · filed 2023-04-27 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-13 | |||
| 2020-12-31 | $6.95B 10-K · filed 2023-02-14 | |||
| 2019-12-31 | $7.99B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $7.99B derived: sum of 2 quarters · filed 2022-02-09 | $26.78B 10-K · filed 2022-02-09 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $18.79B 10-Q · filed 2019-10-31 | ||
| 2019-06-30 | $18.79B 10-Q · filed 2019-07-25 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10 | $0.00 derived: sum of 2 quarters · filed 2021-02-10 | $0.00 derived: sum of 3 quarters · filed 2021-02-10 | $0.00 10-K · filed 2021-02-10 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $0.00 derived: sum of 2 quarters · filed 2019-10-31 | $0.00 10-Q · filed 2019-10-31 | $0.00 derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-25 | $0.00 10-Q · filed 2019-07-25 | $0.00 derived: sum of 3 quarters · filed 2020-02-24 | $0.00 derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-03-31 | $0.00 10-Q · filed 2018-04-26 | $0.00 derived: sum of 2 quarters · filed 2020-02-24 | $0.00 derived: sum of 3 quarters · filed 2020-02-24 | $337.00M derived: sum of 4 quarters · filed 2020-02-24 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $0.00 derived: sum of 2 quarters · filed 2020-02-24 | $337.00M derived: sum of 3 quarters · filed 2020-02-24 | $1.49B 10-K · filed 2020-02-24 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | $337.00M derived: sum of 2 quarters · filed 2018-10-25 | $1.49B 10-Q · filed 2018-10-25 | |
| 2017-06-30 | $337.00M 10-Q · filed 2018-07-26 | $1.49B 10-Q · filed 2018-07-26 | ||
| 2017-03-31 | $1.49B 10-Q · filed 2018-04-26 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-02-25 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $0.00 derived: sum of 2 quarters · filed 2018-02-13 | $1.27B 10-K · filed 2018-02-13 | |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-27 | $1.27B 10-Q · filed 2016-10-27 | ||
| 2015-06-30 | $1.27B 10-Q · filed 2016-07-28 | |||
| 2013-12-31 | $1.48B derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $1.48B derived: sum of 2 quarters · filed 2016-02-12 | $1.48B derived: sum of 3 quarters · filed 2016-02-12 | $1.49B 10-K · filed 2016-02-12 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-24 | $0.00 derived: sum of 2 quarters · filed 2014-10-24 | $12.00M 10-Q · filed 2014-10-24 | $12.00M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-24 | $12.00M 10-Q · filed 2014-07-24 | $12.00M derived: sum of 3 quarters · filed 2015-02-13 | |
| 2013-03-31 | $12.00M 10-Q · filed 2014-04-29 | $12.00M derived: sum of 2 quarters · filed 2015-02-13 | ||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $1.95B 10-K · filed 2015-02-13 | ||
| 2012-09-30 | $1.95B 10-Q · filed 2013-10-23 | |||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $0.00 derived: sum of 2 quarters · filed 2013-02-15 | $6.00M 10-K · filed 2013-02-15 | |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $6.00M 10-Q · filed 2011-10-27 | ||
| 2010-06-30 | $6.00M 10-Q · filed 2011-07-28 | |||
| 2009-12-31 | $1.68B derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | $1.68B derived: sum of 2 quarters · filed 2012-02-17 | $1.68B 10-K · filed 2012-02-17 | |
| 2009-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-22 | $0.00 10-Q · filed 2009-10-22 | ||
| 2009-06-30 | $0.00 10-Q · filed 2009-07-23 | |||
| 2008-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18 | $1.00M derived: sum of 2 quarters · filed 2011-02-18 | $1.58B 10-K · filed 2011-02-18 | |
| 2008-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-22 | $1.58B 10-Q · filed 2009-10-22 | ||
| 2008-06-30 | $1.58B 10-Q · filed 2009-07-23 | |||
| 2007-12-31 | $0.00 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |